Lilly Endowment Awards $10 Million Grant To Fuel Early Development Of Indiana Biosciences Research Institute

Lilly Endowment Awards $10 Million Grant To Fuel Early Development Of Indiana
                        Biosciences Research Institute

PR Newswire

INDIANAPOLIS, June 27, 2013

INDIANAPOLIS, June 27, 2013 /PRNewswire/ --BioCrossroads and the Indiana
Biosciences Research Institute announced today the receipt of a $10 million
grant from Lilly Endowment Inc. to the CICP Foundation, Inc., in support of
the charitable, educational and scientific activities of the Indiana
Biosciences Research Institute. The Institute is a significant new statewide
public-private entity bringing together Indiana's life sciences industry
leaders and academic research institutions through a novel structure to
accelerate Indiana's strengths in the discovery, development and delivery of
bioscience and medical technology innovations.

The Indiana Biosciences Research Institute was incorporated on May 20, 2013,
and officially launched in a public announcement on May 30 by Indiana Governor
Mike Pence and leading statewide life sciences executives and university
leaders. The Institute is the first industry-led biosciences research
institute in the country and serves as the centerpiece project of
BioCrossroads, an initiative that advances the state's life sciences
strengths. It will attract world-class scientific leaders and life sciences
research dollars to Indiana, while focusing on human health solutions for
improving the lives of Hoosiers and people around the world.

"The Indiana Biosciences Research Institute is unlike any research institute
in the nation because our industry leaders have spearheaded its development
and are charting its course," said David L. Johnson, president and CEO of
BioCrossroads and the Central Indiana Corporate Partnership (CICP). "Once
again, Lilly Endowment is instrumental in Indiana's progress through a major
grant that will provide critically needed early support for this game-changing
enterprise and encourage other public, corporate and philanthropic leaders to
do likewise. The Endowment's early investment in the Indiana Biosciences
Research Institute will fuel the Institute's exciting pace of progress and
support our continued efforts to build upon Indiana's strengths in this
premier sector of our economy."

"The Institute will foster deep and strategic collaborations among Indiana's
life science companies and research institutions that should increase and
enhance the state's intellectual capital and strengthen its economy," said N.
Clay Robbins, Lilly Endowment's president and CEO. "The degree of shared
commitment of Indiana's life sciences businesses, its research institutions
and state government to growing the research capacity in Indiana is
unprecedented. Lilly Endowment is pleased to help support the launch of this
exciting new venture that holds great promise for our state."

This $10 million grant from the Lilly Endowment will go to CICP Foundation,
Inc., which supports charitable, educational and scientific activities of
BioCrossroads and other branded initiatives of CICP.

The Indiana Biosciences Research Institute will accelerate and focus
collaboration across and among Indiana's substantial academic and commercial
research assets by attracting nationally – and internationally – significant
talent with a proven track record of academic excellence and success in
advancing innovation and collaboration with industry partners. These "Indiana
Fellows" of the Institute will work in collaboration with one another, as well
as with industry and academic partners, on a focused range of scientific
research projects in the public interest that should lead to substantially
greater public and private research spending in Indiana and accompanying jobs.

As part of the Institute's development process, industry leaders have defined
common scientific interests for research and discovery. The Institute will
initially focus on the most pressing issues of human health: cardiovascular
disease, diabetes, obesity and nutrition. These interrelated metabolic
disorders are a major economic burden and a leading cause of death in the
United States. Approximately 35 percent of Americans suffer from
cardiovascular disease and metabolic disorders, including a disproportionate
percentage of Hoosiers who suffer from these diseases.

The Institute has gained significant momentum in the past eight months, with
an early endorsement from Indiana Governor Mike Pence and active participation
in development by industry leaders from Eli Lilly and Company, Cook Medical,
Dow AgroSciences, Roche Diagnostics, Indiana University Health and Biomet, as
well as university leaders from Purdue University, Indiana University and the
University of Notre Dame. The Indiana General Assembly, in its recent
legislative session, appropriated $25 million for Institute start-up costs.
The Endowment's $10 million grant is a significant step forward in the
Institute's development, to be supplemented with further industry and
philanthropic funds to reach a milestone of $50 million for initial

"The Indiana Biosciences Research Institute continues to gain momentum, and
Lilly Endowment's grant underscores the power of a great idea and
partnerships," said Jack Phillips, president and CEO of Roche Diagnostics. "I
am confident the Institute will meet its philanthropic and corporate funding
goals in short order."

About Lilly Endowment Inc.

Lilly Endowment Inc. is an Indianapolis-based, private philanthropic
foundation created in 1937 by three members of the Lilly family -- J.K. Lilly
Sr. and sons J.K. Jr. and Eli -- through gifts of stock in their
pharmaceutical business, Eli Lilly and Company. While those gifts remain the
financial bedrock of the Endowment, the Endowment is a separate entity from
the company, with a distinct governing board, staff and location. In keeping
with the founders' wishes, the Endowment supports the causes of community
development, education and religion and maintains a special commitment to its
hometown, Indianapolis, and home state, Indiana. More information can be
found at

About BioCrossroads

BioCrossroads ( advances Indiana's signature strengths
in the life sciences by connecting with corporate, academic and philanthropic
partners; facilitating investments in promising start ups and building new
enterprises; and educating through conferences, reports and market development
knowledge. The initiative supports the region's existing research and
corporate strengths while encouraging new business development and has formed
several new nonprofit organizations, including Indiana Health Information
Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX,
OrthoWorx, and Datalys Center.

SOURCE BioCrossroads

Contact: Lori Leroy, BioCrossroads, 317-238-2456 (office) 317-514-0095 (cell),, or Laura Miller, Indiana Biosciences Research
Institute, 317-332-3306,
Press spacebar to pause and continue. Press esc to stop.